Table 1.
Donor | Antigen | Replicate 1 | Replicate 2 | Replicate 3 | Replicate 4 | Replicate 5 | Replicate 6 | Mean | SD | %CV |
---|---|---|---|---|---|---|---|---|---|---|
A | ||||||||||
S09 | BZLF1 | 283 | 267 | 280 | ND | ND | ND | 277 | 8.50 | 3.07 |
S11 | BZLF1 | 432 | 440 | 493 | ND | ND | ND | 455 | 33.15 | 7.29 |
S14 | BZLF1 | 438 | 452 | 479 | ND | ND | ND | 456 | 20.84 | 4.57 |
S16 | BZLF1 | 458 | 374 | 384 | ND | ND | ND | 405 | 45.88 | 11.32 |
S18 | BZLF1 | 110 | 148 | 103 | ND | ND | ND | 120 | 24.21 | 20.12 |
S01 | EBNA3A | 30 | 26 | 31 | ND | ND | ND | 29 | 2.65 | 9.12 |
S10 | EBNA3A | 28 | 31 | 31 | ND | ND | ND | 30 | 1.73 | 5.77 |
S12 | EBNA3A | 38 | 43 | 46 | ND | ND | ND | 42 | 4.04 | 9.55 |
S20 | EBNA3A | 68 | 60 | 81 | ND | ND | ND | 70 | 10.60 | 15.21 |
S21 | EBNA3A | 166 | 158 | 192 | ND | ND | ND | 172 | 17.78 | 10.34 |
S12 | PHA-L | 35 | 35 | 45 | 44 | Rejected | 38 | 39 | 4.83 | 12.25 |
S15 | PHA-L | 718 | 659 | 774 | 685 | 679 | Rejected | 703 | 45.01 | 6.40 |
S21 | PHA-L | Rejected | 715 | 836 | 740 | 786 | 771 | 770 | 46.20 | 6.00 |
S25 | PHA-L | 293 | 326 | 391 | 250 | 276 | Rejected | 307 | 54.37 | 17.70 |
S26 | PHA-L | 98 | 120 | 123 | Rejected | 98 | 123 | 112 | 13.20 | 11.75 |
S27 | PHA-L | 253 | 280 | 284 | 264 | 226 | Rejected | 261 | 23.38 | 8.95 |
Mean | 22.27 | 9.96 | ||||||||
B | ||||||||||
S09 | BZLF1 | 63 | 67 | 52 | ND | ND | ND | 61 | 7.77 | 12.80 |
S11 | BZLF1 | 28 | 27 | 30 | ND | ND | ND | 28 | 1.53 | 5.39 |
S14 | BZLF1 | 37 | 31 | 34 | ND | ND | ND | 34 | 3.00 | 8.82 |
S16 | BZLF1 | 39 | 39 | 43 | ND | ND | ND | 40 | 2.31 | 5.73 |
S18 | BZLF1 | 32 | 37 | 37 | ND | ND | ND | 35 | 2.89 | 8.17 |
S01 | EBNA3A | 33 | 29 | 21 | ND | ND | ND | 28 | 6.11 | 22.08 |
S10 | EBNA3A | 26 | 26 | 20 | ND | ND | ND | 24 | 3.46 | 14.43 |
S12 | EBNA3A | 47 | 44 | 51 | ND | ND | ND | 47 | 3.51 | 7.42 |
S20 | EBNA3A | 41 | 32 | Rejected | ND | ND | ND | 37 | 6.36 | 17.44 |
S21 | EBNA3A | 42 | 38 | 38 | ND | ND | ND | 39 | 2.31 | 5.87 |
S12 | PHA-L | 142 | 148 | 143 | 142 | 112 | Rejected | 137 | 14.42 | 10.49 |
S15 | PHA-L | 718 | 645 | 647 | 718 | 652 | Rejected | 676 | 38.43 | 5.68 |
S21 | PHA-L | Rejected | 685 | 688 | 693 | 725 | 700 | 698 | 16.02 | 2.29 |
S25 | PHA-L | 413 | 410 | 408 | 382 | Rejected | 412 | 405 | 13.00 | 3.21 |
S26 | PHA-L | 488 | 505 | 511 | 554 | 501 | 524 | 514 | 22.96 | 4.47 |
S27 | PHA-L | 374 | 423 | 430 | 445 | 385 | 383 | 407 | 29.59 | 7.28 |
Mean | 10.85 | 8.85 | ||||||||
C | ||||||||||
S09 | BZLF1 | 50 | 51 | 57 | ND | ND | ND | 53 | 3.79 | 7.19 |
S11 | BZLF1 | 19 | 18 | 21 | ND | ND | ND | 19 | 1.53 | 7.90 |
S14 | BZLF1 | 24 | 18 | 18 | ND | ND | ND | 20 | 3.46 | 17.32 |
S16 | BZLF1 | 26 | 23 | 26 | ND | ND | ND | 25 | 1.73 | 6.93 |
S18 | BZLF1 | 23 | 29 | 29 | ND | ND | ND | 27 | 3.46 | 12.83 |
S01 | EBNA3A | 18 | 11 | 11 | ND | ND | ND | 13 | 4.04 | 30.31 |
S10 | EBNA3A | 13 | 18 | 11 | ND | ND | ND | 14 | 3.61 | 25.75 |
S12 | EBNA3A | 23 | 25 | 27 | ND | ND | ND | 25 | 2.00 | 8.00 |
S20 | EBNA3A | 10 | 14 | 16 | ND | ND | ND | 13 | 3.06 | 22.91 |
S21 | EBNA3A | 22 | 17 | 21 | ND | ND | ND | 20 | 2.65 | 13.23 |
S12 | PHA-L | 0 | 0 | 0 | 0 | 0 | 0 | 0 | – | – |
S15 | PHA-L | Rejected | 317 | 372 | 345 | 363 | Rejected | 349 | 24.25 | 6.94 |
S21 | PHA-L | Rejected | 460 | 454 | 437 | Rejected | 489 | 460 | 21.65 | 4.71 |
S25 | PHA-L | 113 | 118 | 124 | Rejected | 125 | Rejected | 120 | 5.60 | 4.66 |
S26 | PHA-L | 66 | 79 | 89 | 68 | 70 | 93 | 78 | 11.43 | 14.75 |
S27 | PHA-L | 175 | 181 | 200 | 189 | 142 | Rejected | 177 | 21.89 | 12.34 |
Mean | 7.61 | 13.05 |
Values represent the number of detected antigen-specific IFNγ (A), IL2 (B) and IFNγ + IL2 (C) SFC/2 × 105 PBMC (stimulated with 1 µg/ml BZLF1 or EBNA3A peptide pools) or mitogen-specific IFNγ (A), IL2 (B) and IFNγ + IL2 (C) SFC/5 × 104 PBMC (stimulated with 2 µg/ml PHA-L) in the IFNγ/IL2 FluoroSpot assay (data is not background subtracted); “rejected” wells were not accepted because they did not pass the quality control
ND not done, SD standard deviation, CV coefficient of variation